ArticleCurrent treatment options in neurology2015
Treatment of sleep-related eating disorder.
Article in Current treatment options in neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Current evidence and future perspectives in the exploration of sleep-related eating disorder-a systematic literature review.Frontiers in psychiatry · 2024Pooled it
- Polysomnography findings in sleep-related eating disorder: a systematic review and case report.Frontiers in psychiatry · 2023Pooled it
- Diagnosis and Management of NREM Sleep Parasomnias in Children and Adults.Diagnostics (Basel, Switzerland) · 2023Review
- An integrative model as a step toward increasing the awareness of eating disorders in the general population.Frontiers in psychiatry · 2023Article
- Metabolic, behavioral health, and disordered eating comorbidities associated with obesity in pediatric patients: An Obesity Medical Association (OMA) Clinical Practice Statement 2022.Obesity pillars · 2022Article
- Medications as a Trigger of Sleep-Related Eating Disorder: A Disproportionality Analysis.Journal of clinical medicine · 2022Article
- Behavior, motivational interviewing, eating disorders, and obesity management technologies: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.Obesity pillars · 2022Article
- Phentermine-topiramate extended release for the dual treatment of obesity and sleep-related eating disorder: a case report.Journal of medical case reports · 2022Article
- Sleep-related eating disorder associated with zolpidem: cases compiled from a literature review.Sleep medicine: X · 2020Review
- Two Cases of Sleep-Related Eating Disorder Responding Promptly to Low-Dose Sertraline Therapy.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2018Article
- Sleep-Related Eating Disorder (SRED): Paradoxical Effect of Clonazepam.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2018Article
- Therapeutic Symptomatic Strategies in the Parasomnias.Current treatment options in neurology · 2018Review
- The effect of agomelatine and melatonin on sleep-related eating: a case report.Journal of medical case reports · 2017Article
- ATS Core Curriculum 2016: Part I. Adult Sleep Medicine.Annals of the American Thoracic Society · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementSleep-related eating disorder (SRED) is classified as an NREM-related parasomnia characterized by recurrent episodes of dysfunctional eating that occur after an arousal from the main sleep period with partial or complete amnesia for the event, resulting in weight gain from eating high calorie foods and causing various injuries due to consumption of inedible or toxic items. SRED can be idiopathic or commonly associated with other primary sleep disorders such as sleepwalking, restless legs syndrome (RLS), obstructive sleep apnea syndrome (OSAS), other clinical conditions, or use of sedative-hypnotic medications. First-line treatment of idiopathic SRED includes selective serotonin reuptake inhibitors (SSRIs) at mean dosages of 20 to 30 mg/day. Topiramate at 100-300 mg/day and clonazepam at 0.5-2.0 mg/day can be valid alternative options. SRED related to other parasomnias or sleep disturbances that cause sleep fragmentation benefit most from treatment of the associated sleep disorder. In particular, RLS-related SRED is best treated with dopamine agonists such as pramipexole, while sleepwalking-related SRED benefits from low-dose benzodiazepines such as clonazepam. Different kinds of drug associations have been proposed in a limited number of cases, especially in the past. We strongly recommend that all patients suffering from SRED should undergo consistent and regular follow-up about 2-3 times per year or otherwise according to the physician's judgment, in order to assess the evolution of symptom severity and frequency and re-evaluate treatment efficacy and any side effects that may arise.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.